

Anniversary Issue Contribution

Thrombosis and cancer: A personal view

Maria Benedetta Donati

Research Laboratories, "John Paul II" Centre for High Technology Research and Education in Biomedical Sciences, Catholic University, Campobasso, Italy

During our Ph.D. studies at the Laboratory of Marc Verstraete, under the guidance of Jos Vermeylen (Leuven University), Giovanni de Gaetano and myself went to visit some US laboratories in 1972, including that of Eugene Clifton at Sloan Kettering in New York. This investigator was indeed one of the pioneers to propose the two-way association between thrombosis and cancer.

This association, described one century earlier by Armand Trousseau in tumors of the gastro-intestinal tract (1), had not been further explored, but warranted both experimental and clinical attention, as Clifton's work had shown in the 1960s (2–6).

Back to Italy in 1973, we were asked to open a new laboratory on haemostasis and thrombosis in Milan at Mario Negri Institute, a non-profit research institution well known at that time for its experimental studies in the field of cancer chemotherapy. We decided therefore to match the experience in the physiopathology of haemostasis and thrombosis – gained during our MD studies at Rome Catholic University with Raffaello Breda and Bruno Bizzi, two pioneers of coagulation studies in Italy, and extended during our five years spent at the Leuven Laboratory – with the experience of Mario Negri Institute investigators in the oncological field.

We started to work there at two levels: cell biology, looking with Luciano Morasca at the procoagulant/fibrinolytic activities of tumors cells (7–9) and animal models, with Andreina Poggi, looking at changes in the haemostatic system of the host during the development of some experimental tumors (10, 11) and on the treatment of murine tumors with antithrombotic drugs (12–14).

A cancer procoagulant

Many studies were focussed on a new procoagulant activity specifically confined to the malignant phenotype, the so-called "Cancer Procoagulant". This factor appeared to be similar to the one described in rabbit V₂ carcinoma by Stuart Gordon's group in Denver, Colorado, and was found by our group in several warfarin-sensitive murine tumors (9, 16, 17) and in human melanoma

cells (18), as well as in different human tumors (19). It was also the main procoagulant activity of acute promyelocytic leukaemia, and a sensitive marker of both disease activity and response to chemotherapy and ATRA treatment (20–22). Cancer procoagulant had been purified from human amniocorial or several malignant tissues as a cysteine protease with a peculiar clotting mechanism by Anna Falanga in Gordon's Laboratory. Despite the effort of several laboratories in the past 20 years, such an important tumor cell procoagulant and malignancy marker, for a number of reasons including technical problems, has not received so far a complete molecular and genetic characterization, which remains open to future research.

Studies in experimental models of tumor growth led us to the definition of the type of thrombocytopenia and anaemia associated with the growth of the primary site in some murine tumors (10, 11) and to the discovery that warfarin could exert a peculiar antimetastatic effect in some models, possibly due to the inhibition of cancer procoagulant, characterized as a novel vitamin K-dependent factor (16, 17, 24). Other studies in mice, with Nicola Semeraro, Alberto Mantovani, Mario Colucci and Roberto Lorenzet, led us to realize how important tumor/host interactions were in the expression of a "physiological" extravascular procoagulant such as tissue factor (TF) with consequent fibrin deposition at the tumor/host interface (25, 26). These studies pioneered a large series of experiments on inflammation, cancer and host antitumor defence mechanisms.

Despite the progress our group and few others had accomplished in the field, the association of thrombosis and cancer was mainly considered, till the end of the 1970s, the concern of some "exoteric" investigators and the presentations proposed at haemostasis and thrombosis meetings were regularly ranked as "other" or "miscellaneous". As they were not included in any major category, they were usually accepted as posters, to be presented during the less important sessions. A honourable exception was the 1979 Congress of the International Society on Thrombosis and Haemostasis (ISTH) in London, where the late Arthur Bloom organized a symposium on "Malignancy and Haemostasis", I was asked to chair together with John Davidson (27). The increasing interest of our group into "cellular aspects of haemos-

Correspondence to:
Maria B. Donati
Research Laboratories
"John Paul II" Centre for High Technology Research
and Education in Biomedical Sciences
Catholic University
C. da Tappino, 86100 Campobasso, Italy
Tel.: +39 0874 312278, Fax: +39 0874 312710
E-mail: mbdonati@rm.unicatt.it

Received May 22, 2007
Accepted May 23, 2007

Prepublished online June 12, 2007
doi:10.1160/TH07-05-0363

tasis”, was also reflected by the “Bizzozzero Symposium” organized together with Peter Mannucci in Bergamo (1982) on the occasion of the 28th ISTH SubCommittee meeting.

In 1983, within the ISTH, we succeeded in establishing a new SSC SubCommittee devoted to “Malignancy and Haemostasis”. Its first chairman was Yale Nemerson. I took the chair in the subsequent years (1985–1988), followed then by Graham Jamieson, Fred Rickles, Mark Levine, Ajay Kakkar, Anna Falanga and Martin Prinz (2007). These SubCommittee meetings gradually moved from 20–30 attendees to over 300.

From experimental models to clinical trials

The real switch was determined by the growing interest of clinical oncologists in the association between thrombosis and cancer, along two main lines:

- The association of thrombosis with cancer treatment, not only surgery, but chemotherapy and hormone therapy as well. This concern has lately been extended to the risk of thrombosis associated with anti-angiogenic therapy (28–31).
- The observation of idiopathic or unprovoked venous thrombosis as a predictor of the clinical manifestation of an occult cancer (32–34).

These two clinical issues have prompted new research and inspired experimental work in the last few years. Meanwhile, the work of the SubCommittee had led to the establishment, in collaboration with Leo Zacharski, of a Registry of Clinical Trials of Antithrombotic Drugs in cancer patients, first published in 1989 (35) and updated in 1993 (36). The Registry clearly showed a very messy situation in a period when, in other fields such as the cardiovascular one, the application of modern clinical trial methodology had allowed to reach important goals for prevention and treatment of ischaemic heart disease (37–38).

Indeed, at the experimental level, evidence had been collected to suggest that modification of the host's haemostatic system by different pharmacological approaches could lead to changes in the degree and speed of tumor and metastasis growth (12–14). The data could be schematically summarized as follows: Whatever antithrombotic drug or condition, such as antiplatelet antibodies or dysfunctional platelets, would reduce blood cell stickiness and/or increase blood fluidity, would also delay and reduce the trapping of tumor cells within the lungs of the host by diverting cancer cells towards the spleen or the liver, to be destroyed there by the reticulo-endothelial system. As a result, the subsequent growth of lung metastasis would be significantly delayed or inhibited (12, 14, 39, 40). These data did not find initially any translation into clinical application, and for many years a striking lack of appropriate clinical trials was reflected in the SSC Registry.

One of the major difficulties to prove the effectiveness of anticoagulants in cancer patients was that the use of antivitamin K drugs – remarkably effective in some animal models (13, 16, 24) – required laboratory monitoring and induced serious haemorrhagic risk in patients with cancer, who are often thrombocytopenic due to chemotherapy and/or radiotherapy.

The development of low-molecular-weight heparins (LMWH) in the prevention/treatment of thrombosis in cancer patients, has lately made available a more patient-friendly antithrombotic treatment in these patients. The favourable experience with LMWH opened indeed the way to new trials with heparins to modify the natural history of several tumors (42, 43). This happened during the last few years and is still going on. From preliminary data available in the first trials (44–47) it would appear that LMWH treatment could delay metastasis growth in different tumors, but only if the tumor is still at an early stage. This finding, confirmed by trials with different design and treatment schedules (44–47), may be explained by the following hypothesis: LMWH would act on the dissemination of tumor cells by anti-adhesive/anti-inflammatory properties (different at least in part from their anticoagulant activity); these properties would enable LMWH to prevent the adhesion of tumor cells to the vascular wall and their extravasation to form metastatic foci. Once metastases have been formed, however, LMWH would be unable to prevent their growth. For this reason only tumors at a relatively early stage, i.e. with still a significant burden of circulating tumor cells, would respond to the inhibitory or delaying effects of LMWH. This hypothesis is supported by recent *in vitro* data showing the ability of some LMWH to prevent cell-cell interactions, relevant for the adhesion of cancer cells to the vascular wall and subsequent extravasation (48, 49). Old experimental work in mice had already shown the best time window of treatment with heparin to obtain an anti-metastatic activity: This effect was indeed only observed when tumor cells were injected intravenously in mice pretreated with heparin (40).

Conclusions

The relationships between thrombosis and cancer are a paradigmatic example of the useful cross-talk between experimental data and clinical results: many years after the reports on beneficial heparin effects in experimental tumor models (4, 5), recent clinical results (44–47) prompted us to go back to experimental systems, to find out the best conditions for heparin to favourably modify the natural history of some human tumors. Presently, these studies need to carefully consider the mechanism of heparin's action in relation to both tissue factor expression by cancer and host cells and the angiogenic response, two areas of significant progress in recent years (50–52). Although studies on the association between thrombosis and cancer are no more confined to few laboratories, the great number of open questions at experimental and clinical levels will certainly keep the scientific community busy for many years to come.

Acknowledgments

It would be difficult to individually acknowledge all co-workers who contributed during the last four decades to the research developed in my laboratory on haemostasis, thrombosis and cancer. The name of many of them can be found in the reference list. This manuscript was prepared with the careful assistance of Milena Rosiello and the support of a grant from the Italian Research Ministry (MIUR, Decreto no, 1588).

References

1. Trousseau A. Phlegmasia Alba Dolens. Clinique Médicale de l'Hôtel Dieu de Paris, 2nd edition. Vol 3. Paris, JB Baillière, 1865: 659–712.
2. Clifton EE, Grossi CE. Fibrinolytic activity of human tumors as measured by the fibrin-plate method. *Cancer* 1955; 8:1146–1154.
3. Grossi CE, Agostino D, Clifton EE. The effect of human fibrinolysin on pulmonary metastases of Walker 256 carcinoma. *Cancer Res* 1960; 20: 605–608.
4. Agostino D, Grossi CE, Clifton EE. Effect of heparin on circulating Walker carcinosarcoma 256 cells. *J Natl Cancer Inst* 1961; 5: 463–473.
5. Clifton EE, Agostino D. Factors affecting the development of metastatic cancer. Effect of alterations in clotting mechanism. *Cancer* 1962; 15: 276–283.
6. Agostino D, Clifton EE, Girolami A. Effect of prolonged coumadin treatment on the production of pulmonary metastases in the rat. *Cancer* 1966; 19: 284–288.
7. Dolfini E, Azzarone B, Pedulla D, et al. Characterization of human fibroblasts from cancer patients: Loss of fibrin clot retractile activity after 'in vitro' spontaneous transformation. *Eur J Cancer* 1976; 12: 823–825.
8. Donati MB, Dolfini E, Morasca L, et al. Fibrin clot retraction by a rat rhabdomyosarcoma cell line. *Thromb Res* 1976; 8: 707–711.
9. Curatolo L, Colucci M, Cambini AL, et al. Evidence that cells from experimental tumours can activate coagulation factor X. *Br J Cancer* 1979; 40: 228–233.
10. Poggi A, Polentarutti N, Donati MB, et al. Blood coagulation changes in mice bearing Lewis lung carcinoma, a metastasizing tumor. *Cancer Res* 1977; 37: 272–277.
11. Chmielewska J, Poggi A, Mussoni L, et al. Blood coagulation changes in JW sarcoma, a new metastasizing tumour in mice. *Eur J Cancer* 1980; 16: 1399–1407.
12. Mussoni L, Poggi A, de Gaetano G, et al. Effect of diltazole, an inhibitor of platelet aggregation, on a metastasizing tumour in mice. *Br J Cancer* 1978; 37: 126–129.
13. Poggi A, Mussoni L, Kornblihtt L, et al. Warfarin enantiomers, anticoagulation, and experimental tumor metastasis. *Lancet* 1978; 1: 163–164.
14. Chmielewska J, Poggi A, Janik P, et al. Effect of defibrination with batroxobin on growth and metastasis of JW sarcoma in mice. *Eur J Cancer* 1980; 16: 919–923.
15. Gordon SG, Franks JJ, Lewis B. Cancer procoagulant A: a factor X-activating procoagulant from malignant tissue. *Thromb Res* 1975; 6: 127–137.
16. Colucci M, Delaini F, De Bellis Vitti G, et al. Warfarin inhibits both procoagulant activity and metastatic capacity of Lewis lung carcinoma cells. Role of vitamin K deficiency. *Biochem Pharmacol* 1983; 32: 1689–1691.
17. Lorenzet R, Bottazzi B, Locati D, et al. Failure of warfarin to affect the tissue factor activity and the metastatic potential of murine fibrosarcoma cells. *Eur J Cancer Clin Oncol* 1985; 21: 263–265.
18. Donati MB, Gambacorti P, Casali B, et al. Cancer procoagulant in human tumor cells: Evidence from melanoma patients. *Cancer Res* 1986; 46: 6471–6474.
19. Grignani G, Falanga A, Pacchiarini L, et al. Human breast and colon carcinomas express cysteine proteinase activities with pro-aggregating and pro-coagulant properties. *Int J Cancer* 1988; 42: 554–557.
20. Falanga A, Alessio MG, Donati MB, et al. A new procoagulant in acute leukemia. *Blood* 1988; 71: 870–875.
21. Donati MB, Falanga A, Consonni R, et al. Cancer procoagulant in acute non lymphoid leukemia: Relationship of enzyme detection to disease activity. *Thromb Haemost* 1990; 64: 11–16.
22. Falanga A, Iacoviello L, Evangelista V, et al. Loss of blast cell procoagulant activity and improvement of hemostatic variables in patients with acute promyelocytic leukemia administered all-trans-retinoic acid. *Blood* 1995; 86: 1072–1081.
23. Falanga A, Gordon SG. Isolation and characterization of cancer procoagulant: a cysteine proteinase from malignant tissue. *Biochemistry* 1985; 24: 5558–5567.
24. Roncaglioni MC, D'Alessandro AP, Casali B, et al. Gamma-glutamyl carboxylase activity in experimental tumor tissues: a biochemical basis for vitamin K dependence of cancer procoagulant. *Haemostasis* 1986; 16: 295–299.
25. Lorenzet R, Peri G, Locati D, et al. Generation of procoagulant activity by mononuclear phagocytes: A possible mechanism contributing to blood clotting activation within malignant tissues. *Blood* 1983; 62: 271–273.
26. Rambaldi A, Alessio G, Casali B, et al. Induction of monocyte-macrophage procoagulant activity by transformed cell lines. *J Immunol* 1986; 136: 3848–3855.
27. Donati MB, Davidson JD, Garattini S. Malignancy and the Hemostatic System. Raven Press, N.Y. 1981.
28. Levine MN, Gent M, Hirsh J, et al. The thrombogenic effect of anticancer drug therapy in women with stage II breast cancer. *N Engl J Med* 1988; 318: 404–407.
29. Levine M, Hirsh J, Gent M, et al. Double-blind randomized trial of a very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer. *Lancet* 1994; 343: 886–889.
30. Barbui T, Falanga A. Thalidomide and thrombosis in multiple myeloma. *J Thromb Haemost* 2003; 3: 421–422.
31. Donati MB, Falanga A. Pathogenetic mechanisms of thrombosis in malignancy. *Acta Haematol* 2001; 106: 18–24.
32. Prandoni P, Lensing AW, Buller HR et al. Deep-vein thrombosis and the incidence of subsequent symptomatic cancer. *N Engl J Med* 1992; 327: 1128–1133.
33. Prandoni P, Falanga A, Piccioli A. Cancer and venous thromboembolism. *Lancet Oncol* 2005; 6: 401–410.
34. Lee AYY. Thrombosis and cancer: The role of screening for occult cancer and recognizing the underlying biological mechanisms. In: *Hematology 2006*, Am Soc Hemat, Education Program Book, Bajus JL. Ed. p 438–443.
35. Zacharski LR, Donati MB. Registry of clinical trials of antithrombotic drugs in cancer. The Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Subcommittee on Hemostasis and Malignancy. *Thromb Haemost* 1989; 61: 526–528.
36. Zacharski LR, Donati MB, Rickles FR. Registry of clinical trials of antithrombotic drugs in cancer: Second report. *Thromb Haemost* 1993; 70: 357–360.
37. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction:ISIS-2.ISIS-2 (Second International Study of Infarct Survival). Collaborative Group. *Lancet* 1988; 2: 349–360.
38. GISSI-2: a factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12,490 patients with acute myocardial infarction. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardio. *Lancet* 1990; 336: 65–71.
39. Donati MB, Poggi A. Malignancy and haemostasis. *Br J Haematol* 1980; 44: 173–182.
40. Poggi A, Donati MB, Garattini S. Fibrin and cancer cell growth: Problems in the evaluation of experimental models. In: *Malignancy and the hemostatic system*, Raven Press, New York, 1981: pp. 89–101.
41. Bani MR, Falanga A, Alessio MG, et al. Blood coagulation changes in nude mice bearing human colon carcinomas. *Int J Cancer* 1992; 50: 75–79.
42. Falanga A. The effect of anticoagulant drugs on lung cancer. *J Thromb Haemost* 2004; 2: 1263–1265.
43. Lee AY, Levine MN, Baker RI, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. *N Engl J Med* 2003; 349: 146–153.
44. Altinbas M, Coskun HS, Er O, et al. A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer. *J Thromb Haemost* 2004; 2: 1266–1271.
45. Kakkar AK, Levine MN, Kadziola Z, et al. Low molecular weight heparin therapy with dalteparin and survival in advanced cancer: the framing advanced malignancy outcome study (FAMOUS). *J Clin Oncol* 2004; 22: 1944–1948.
46. Klerk CP, Smorenburg SM, Otten HM, et al. The effect of low molecular weight heparin on survival in patients with advanced malignancy. *J Clin Oncol* 2005; 23: 2130–2135.
47. Lee AY, Rickles FR, Julian JA, et al. Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. *J Clin Oncol* 2005; 23: 2123–2129.
48. Maugeri N, de Gaetano G, Barbanti M, et al. Prevention of platelet-polymorphonuclear leukocyte interactions: new clues to the antithrombotic properties of parnaparin, a low molecular weight heparins. *Haematologica* 2005; 90: 815–821.
49. Maugeri N, Di Fabio G, Barbanti M, et al. Parnaparin, a low molecular weight heparin, prevents P-selectin-dependent formation of platelet-leukocyte aggregates in human whole blood. *Thromb Haemost* 2007; 97: 965–973.
50. Lorenzet R, Donati MB. Blood clotting activation, angiogenesis and tumor metastasis: any role for TFPI? *Thromb Haemost* 2002; 87: 928–929.
51. Donati MB, Lorenzet R. Coagulation factors and tumor cell biology: the role of tissue factor. *Pathophysiol Haemost Thromb* 2003; 33 (Suppl 1): 22–25.
52. Donati MB, Falanga A, Lorenzet R. Cancer and thrombosis: a two way interaction. In: *Thrombosis. Fundamental and clinical aspects*. Leuven University Press, 2003: pp. 417–31.